Monoclonal Gammopathy of Undetermined Significance (MGUS) and smoldering multiple myeloma

Myeloma: Pathology, Diagnosis, and Treatment

Volumn , Issue , 2011, Pages 121-133

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924305601     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511862465.010     Document Type: Chapter

References (56)

1. Kyle, R. A. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am. J. Med. 1978; 64(5):814–26.
2. Kyle, R. A., Greipp, P. R. Smoldering multiple myeloma. N. Engl. J. Med. 1980;302(24): 1347–9.
3. Alexanian, R. Localized and indolent myeloma. Blood 1980;56 (3):521–5.
4. Kyle, R. A., Durie, B. G., Rajkumar, S. V., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121–7.
5. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003;121 (5):749–57.
6. Merlini, G., Stone, M. J. Dangerous small B-cell clones. Blood 2006;108(8):2520–30.
7. Waldenstrom, J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211–31.
8. Dammacco, F., Waldenstrom, J. Bence Jones proteinuria in benign monoclonal gammopathies. Incidence and characteristics. Acta Med. Scand. 1968;184(5):403–9.
9. Axelsson, U., Bachmann, R., Hallen, J. Frequency of pathological proteins (M-components) on 6,995 sera from an adult population. Acta Med. Scand. 1966;179(2):235–47.
10. Saleun, J. P., Vicariot, M., Deroff, P., Morin, J. F. Monoclonal gammopathies in the adult population of Finistere, France. J. Clin. Pathol. 1982;35(1):63–8.
11. Kyle, R. A., Finkelstein, S., Elveback, L. R., Kurland, L. T. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972;40(5):719–24.
12. Landgren, O., Gridley, G., Turesson, I. et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107 (3):904–6.
13. Kyle, R. A., Therneau, T. M., Rajkumar, S. V. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2006;354(13):1362–9.
14. Kyle, R. A., Therneau, T. M., Rajkumar, S. V. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 2002;346(8):564–9.
15. Dispenzieri, A., Katzmann, J. A., Kyle, R. A. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010;375 (9727):1721–8.
16. Landgren, O., Kyle, R. A., Pfeiffer, R. M. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113 (22):5412–17.
17. Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113 (22):5418–22.
18. Rajkumar, S. V., Kyle, R. A., Therneau, T. M. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812–17.
19. Rossi, F., Petrucci, M. T., Guffanti, A. et al. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin. Cancer Res. 2009;15(13):4439–45.
20. Perez-Persona, E., Vidriales, M. B., Mateo, G. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110(7):2586–92.
21. Chiecchio, L., Dagrada, G. P., Ibrahim, A. H. et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009;94(12): 1708–13.
22. Chiecchio, L., Dagrada, G. P., Protheroe, R. K. et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica 2009;94(7):1024–8.
23. Zhan, F., Hardin, J., Kordsmeier, B. et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99(5):1745–57.
24. Zhan, F., Barlogie, B., Arzoumanian, V. et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2000;109 (4):1692–700.
25. Pichiorri, F., Suh, S. S., Ladetto, M. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl Acad. Sci. USA 2008;105(35):12885–90.
26. Pichiorri, F., Suh, S. S., Rocci, A. et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18(4):367–81.
27. Politou, M., Terpos, E., Anagnostopoulos, A. et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br. J. Haematol. 2004;126(5):686–9.
28. Anagnostopoulos, A., Eleftherakis-Papaiakovou, V., Kastritis, E. et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br. J. Haematol. 2007;137(6):560–8.
29. Hillengass, J., Zechmann, C., Bauerle, T. et al. Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin. Cancer Res. 2009;15(9):3118–25.
30. Hose, D., Moreaux, J., Meissner, T. et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009;114(1):128–43.
31. Landgren, O., Kyle, R. A., Hoppin, J. A. et al. Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 2009;113(25):6386–91.
32. Brown, L. M., Gridley, G., Check, D., Landgren, O. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008;111 (7):3388–94.
33. Weiss, B. M., Minter, A., Abadie, J. et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients. Am. J. Hematol. 2011;86(6):475–8.
34. Landgren, O., Linet, M. S., McMaster, M. L. et al. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int. J. Cancer 2006;118 (12):3095–8.
35. Vachon, C. M., Kyle, R. A., Therneau, T. M. et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114(4):785–90.
36. Kristinsson, S. Y., Pfeiffer, R. M., Bjorkholm, M. et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115(24):4991–8.
37. Kristinsson, S. Y., Tang, M., Pfeiffer, R. M. et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 2010;116(15):2651–5.
38. Blade, J., Dimopoulos, M., Rosinol, L., Rajkumar, S. V., Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 2010;28(4):690–7.
39. Kyle, R. A., Remstein, E. D., Therneau, T. M. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007;356(25):2582–90.
40. Dispenzieri, A., Kyle, R. A., Katzmann, J. A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2): 785–9.
41. Rosinol, L., Blade, J., Esteve, J. et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br. J. Haematol. 2003;123(4): 631–6.
42. Rosinol, L., Carrio, A., Blade, J. et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br. J. Haematol. 2005;130(5):729–32.
43. Moulopoulos, L. A., Dimopoulos, M. A., Smith, T. L. et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J. Clin. Oncol. 1995;13(1):251–6.
44. Hillengass, J., Fechtner, K., Weber, M. A. et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J. Clin. Oncol. 2010;28(9): 1606–10.
45. Blade, J., Rosinol, L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr. Treat. Options Oncol. 2006;7 (3):237–45.
46. Hjorth, M., Hellquist, L., Holmberg, E. et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. Eur. J. Haematol. 1993;50(2):95–102.
47. Grignani, G., Gobbi, P. G., Formisano, R. et al. A prognostic index for multiple myeloma. Br. J. Cancer 1996;73(9):1101–7.
48. Riccardi, A., Mora, O., Tinelli, C. et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br. J. Cancer 2000;82(7):1254–60.
49. Rajkumar, S. V., Gertz, M. A., Lacy, M. Q. et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17(4):775–9.
50. Weber, D., Rankin, K., Gavino, M., Delasalle, K., Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 2003;21(1):16–19.
51. Barlogie, B., van Rhee, F., Shaughnessy, J. D., Jr. et al. Sevenyear median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112(8): 3122–5.
52. Musto, P., Falcone, A., Sanpaolo, G. et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk. Lymphoma 2003;44(9): 1545–8.
53. D’Arena, G., Gobbi, P. G., Broglia, C. et al. Pamidronate versus observation in asymptomatic myeloma: final results with longterm follow-up of a randomized study. Leuk. Lymphoma 2011;52 (5):771–5.
54. Musto, P., Petrucci, M. T., Bringhen, S. et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008;113(7):1588–95.
55. Mateos, M.-V., Lopez-Corral, L., Hernandez, M. et al. Smoldering multiple myeloma (SMM) at highrisk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide– dexamethasone (len–dex) as induction therapy followed by maintenance therapy with len alone vs no treatment. ASH Annual Meeting Abstracts 2010;116(21):1935.
56. Lust, J. A., Lacy, M. Q., Zeldenrust, S. R. et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}- induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 2009;84(2):114–22.